Navigation Links
JCI early table of contents for Jan. 9, 2013
Date:1/9/2013

Small peptide ameliorates autoimmune skin blistering disease in mice

Pemphigus vulgaris is a life-threatening autoimmune skin disease that is occurs when the body's immune system generates antibodies that target proteins in the skin known as desomogleins. Desmogleins help to form the adhesive bonds that hold skin cells together and keep the skin intact. Currently, pemphigus vulgaris is treated by long-term immune suppression; however, this can leave the patient susceptible to infection. In this issue of the Journal of Clinical Investigation, researchers led by Jens Waschke at the Institute of Anatomy and Cell Biology in Munich, Germany, report on a small peptide that blocked antibody recognition of desmogleins. Importantly, the peptide could prevent antibody-mediated skin blistering when applied topically to mice. At the cellular level, the peptide improved cell-cell adhesion and attenuated signaling pathways that are activated by antibody binding. These results suggest that this peptide could serve as a treatment option for pemphigus vulgaris.

TITLE:
Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering

AUTHOR CONTACT:
Jens Waschke
Ludwig-Maximilians-University Munich, Munich, , DEU
Phone: 0049-89-5160-4811; Fax: 0049-89-5160-4802; E-mail: jens.waschke@med.uni-muenchen.de

View this article at: http://www.jci.org/articles/view/60139?key=b333192372ea9937c9be


A new treatment for kidney disease-associated heart failure?

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein klotho (klotho hypomorphic mice) also develop vascular calcification and have shorter life spans compared to normal mice. In this issue of the Journal of Clinical Investigation, Florian Lang and colleagues at the University of Tbingen in Germany, found that treatment with the mineralocorticoid receptor antagonist spironolactone reduced vascular calcification in klotho hypomorphic mice and increased their life span. In a companion Attending Physician article, Darryl Quarles of the University of Tennessee discusses the implications of these findings for the treatment of CKD patients.

TITLE:
Spironolactone-sensitive vascular calcification and Pit-1-dependent osteoblastic differentiation in klotho-hypomorphic mice

AUTHOR CONTACT:
Florian Lang
Dept. of Physiology, Tuebingen, NULL, DEU
Phone: +4970712972194; Fax: +497071295618; E-mail: florian.lang@uni-tuebingen.de

View this article at: http://www.jci.org/articles/view/64093?key=3010c850d2f970ad6617

ACCOMPANYING THE ATTENDING PHYSICIAN

TITLE:
Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new

AUTHOR CONTACT:
Darryl Quarles
University of Tennessee Health Science Center, memphis, TN, USA
Phone: 901-448-1459; Fax: 901-448-1188; E-mail: dquarles@uthsc.edu

View this article at: http://www.jci.org/articles/view/67203?key=054ae63743c930253936


New fusion gene contributes to glioblastoma progression

Fusion genes are common chromosomal aberrations in many cancers, and can be used as prognostic markers and drug targets in clinical practice. In this issue of the Journal of Clinical Investigation, researchers led by Matti Annala at Tampere University of Technology in Finland identified a fusion between the FGFR3 and TACC3 genes in human glioblastoma samples. The protein produced by this fusion gene promoted tumor growth and progression in a mouse model of glioblastoma, while increased expression of either of the normal genes did not alter tumor progression. Ivan Babic and Paul Mischel of the University of California, San Diego, explain in the accompanying commentary that it remains unclear how this fusion protein mediates tumorigenesis.

TITLE:
The tumorigenic fusion FGFR3-TACC3 escapes miR-99a regulation in glioblastoma

AUTHOR CONTACT:
Matti Annala
Tampere University of Technology, Tampere, FIN
Phone: +358415079885; E-mail: matti.annala@tut.fi

View this article at: http://www.jci.org/articles/view/67144?key=b644a26bcc8a516cd41d

ACCOMPANYING COMMENTARY

TITLE:
Multiple functions of a glioblastoma fusion oncogene

AUTHOR CONTACT:
Paul Mischel
UCSD, La Jolla, CA, USA
Phone: (858) 534-6080; Fax: ; E-mail: pmischel@ucsd.edu

View this article at: http://www.jci.org/articles/view/67658?key=0186fce1cd2ddde6082f


ALSO IN THIS ISSUE

TITLE:
Type 1 diabetes patients exhibit altered cerebral metabolism during hypoglycemia

AUTHOR CONTACT:
Bastiaan de Galan
Radboud University Nijmegen Medical Centre, Nijmegen, UNK, NLD
Phone: +31243618819; Fax: +31243541734; E-mail: b.degalan@aig.umcn.nl

View this article at: http://www.jci.org/articles/view/62742?key=9b86666385df6bd2593b

TITLE:
Regulation of dendritic cell activation by microRNA let-7c and BLIMP1

AUTHOR CONTACT:
Betty Diamond
The Feinstein Institute for Medical Research, Manhasset, NY, USA
Phone: 516-562-3830; Fax: 516-562-2953; E-mail: bdiamond@nshs.edu

View this article at: http://www.jci.org/articles/view/64712?key=6599e97537112226049c

TITLE:
Liver acid sphingomyelinase inhibits growth of metastatic colon cancer

AUTHOR CONTACT:
Yosuke Osawa
Gifu University Graduate School of Medicine, Gifu, JPN
Phone: 81-58-230-6217; Fax: 81-58-230-6218; E-mail: osawa-gif@umin.ac.jp

View this article at: http://www.jci.org/articles/view/65188?key=4dc45a19d2e16fb3b7c9

TITLE:
Specialized role of migratory dendritic cells in peripheral tolerance induction

AUTHOR CONTACT:
Juliana Idoyaga
The Rockefeller University, New York, NY, USA
Phone: 212-327-7863; Fax: 212-327-8875; E-mail: ijuliana@rockefeller.edu

View this article at: http://www.jci.org/articles/view/65260?key=843f605de298ce5048b3


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. New Stool Test Might Aid in Early Detection of Colon Cancer
2. An Early Start for Your Child with Autism
3. Early Study Finds Some Promise for Lung Cancer Vaccine
4. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
5. JCI early table of contents for April 9, 2012
6. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. First contact: Early intervention key in diagnosis and treatment of serious mental illness
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma ... plan partners, announced during the 2017 Annual HIMSS Conference & Exhibition ... for diabetic patients and integrating eye care into mainstream healthcare delivery is powered ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... -- Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, ... market is expected to grow at a CAGR of 9.4% from ... to grow at a CAGR of 9.5% from 2017 to 2027. ... 2026. ... report will benefit you Read on to discover how you ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology: